Table 4.
Outcome parameters reported among the included studies
| Outcome | Type of participants | Study | Results |
|---|---|---|---|
| Number of good quality embryos | POR | Barad 2022 [21] |
Before PRP 32.1% GI 14.9% GII After PRP 35.8% GI 7.4% GII |
| Sfakianoudis 2020 [29] |
Before PRP 8/18 (44.4%) After PRP28/58 (48.2%) |
||
| Pacu 2021 [27] |
Before PRP 0.33 ± 0.49 After PRP 0.76 ± 0.75 P value 0.073 |
||
| Spontaneous pregnancy | POR | Aflatoonian 2021 [20] | After PRP 8/17 |
| Cakiroglu 2022 [23] | After PRP 22/510 | ||
| Navali 2022 [26] | After PRP 3/30 | ||
| Petryk 2020 [28] | After PRP 4/38 | ||
| POI | Aflatoonian 2021 [20] | After PRP 0/9 | |
| Cakiroglu 2020 [22] | After PRP 23/311 | ||
| Sfakianoudis 2020 [29] | After PRP 8/55 (3/18 POI,4/24 perimenopausal, 1/13 menopausal) | ||
| Fertilization rate | POR | Cakiroglu 2022 [23] |
Before PRP 57.6% After PRP 66.9% P value 0.008 |
| Tulik 2022 [33] |
Before PRP 24/58 After PRP 104/144 P value 0.976 |
||
| Stojkovska 2019 [31] |
Cases 80.67 ± 25.42 Control 65.6 ± 25.35 P value 0.44 |
||
| POI | Cakiroglu 2022 [23] | After PRP 55.8 ± 29.1 | |
| Tulik 2022 [33] | After PRP 0.77 ± 0.72 | ||
| Clinical pregnancy rate | POR | Cakiroglu 2022 [23] | After PRP 83/276 |
| Petryk 2020 [28] | After PRP 7/13 | ||
| Sfakianoudis 2020 [29] | After PRP 14/30 | ||
| Farimani 2021 [24] | After PRP 28/287 | ||
| Pacu 2021 [27] | After PRP 2/20 | ||
| Tulik 2022 [33] |
Before PRP 1/50 After PRP 7/84 P value 0.16 |
||
| Melo 2020 [25] |
Cases 11/46 Control 1/37 |
||
| Stojkovska 2019 [31] |
Cases 33.33 ± 44.99 Control 10.71 ± 28.95 P value 0.69 |
||
| POI | Cakiroglu 2020 [22] | 13/57 (7/28 fresh, 6/29 frozen ET) | |
| Chemical pregnancy rate | POR | Barad 2022 [21] | After PRP 6/80 |
| Petryk 2020 [28] | After PRP 7/13 | ||
| Melo 2020 [25] |
Cases 12/46 Control 2/37 |
||
| Live birth rate | POR | Aflatoonian 2021 [20] | After PRP 4/17 |
| Barad 2022 [21] | After PRP 2/80 | ||
| Cakiroglu 2022 [23] | After PRP 12/510 spontaneous 54/276 IVF | ||
| Petryk 2020 [28] | After PRP 6/13 | ||
| Sfakianoudis 2020 [29] | After PRP 12/30 | ||
| Pacu 2021 [27] | After PRP 2/20 | ||
| Tulik 2022 [33] |
Before PRP 0/50 After PRP 4/84 P value 0.296 |
||
| Melo 2020 [25] |
Cases 4/46 Control 1/37 |
||
| Stojkovska 2019 [31] |
Before PRP 40 ± 50.71 14.29 ± 36.31 P value 0.71 |
||
| POI | Cakiroglu 2020 [22] | After PRP 16/311 spontaneous 9/87 IVF |
POI Premature ovarian insufficiency, POR Poor ovarian response, PRP Platelet rich plasma